← Russell 3000 cross-section

DTIL PRECISION BIOSCIENCES INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$229m
Revenue TTM
$45m
Net income TTM
$-53m
Free cash flow
$-52m
Composite score
Sector rank
#2806

Valuation

P / E
EV / EBITDA
EV / sales
3.1
FCF yield
-22.64%
Earnings yield vs 10-yr
-27.71pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-117.0%
EBITDA margin
ROE
-116.4%
ROIC
Revenue growth
3,473.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements, and potential fines for noncompliance of up to €20 million / £17.5 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. We are subject to increased costs as a result of operating as a public company, and our management will be required to devote substantial time to maintaining compliance initiatives and corporate governance practices, including establishing and maintaining proper and effective internal control over financial reporting.PRECISION BIOSCIENCES INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →